Lapatinib Impurity 9;202196-46-1
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Number: L079009
English Name: Lapatinib Impurity 9
English Alias: 5-(4-((4-(benzyloxy)phenyl)amino)quinazolin-6-yl)furan-2-carbaldehyde
CAS Number: 202196-46-1
Molecular Formula: C₂₆H₁₉N₃O₃
Molecular Weight: 421.45
Product Advantages: Lapatinib Impurity 9 has high purity and good chemical stability. Its structure is accurately confirmed by precise analytical methods such as nuclear magnetic resonance and mass spectrometry. Under different experimental conditions and storage environments, this impurity remains stable and uniform. As a reference substance, it can be used for accurate Lapatinib impurity analysis, ensuring the accuracy and repeatability of detection results, and providing a reliable basis for pharmaceutical quality control and research.
Application Fields:
Quality Control: As an impurity reference standard, it is used to establish and validate the detection methods for impurities in Lapatinib bulk drugs and formulations, ensuring that the sensitivity and specificity of the detection methods meet pharmaceutical quality standards and guaranteeing the consistency of drug quality.
Process Optimization: During the production of Lapatinib, by monitoring the content of this impurity and analyzing the reaction steps that generate it, it assists in optimizing the synthesis process, reducing impurity formation, and improving product quality and production efficiency.
Stability Studies: In drug stability tests, it studies the change rules of this impurity under different storage conditions (such as temperature, humidity, light), providing key data for determining the shelf life and storage conditions of drugs.
Background Description: Lapatinib is an important targeted drug for the treatment of HER2-positive breast cancer. In the process of its research, development, production, and quality control, impurity research is a key link to ensure drug safety and effectiveness. The presence of impurities may affect the activity, safety, and stability of the drug. As a related impurity of Lapatinib, in-depth research on Lapatinib Impurity 9 helps to comprehensively evaluate the quality of Lapatinib drugs and ensure the safety of patients' medication and the therapeutic effect.
Research Status: Currently, research on Lapatinib Impurity 9 mainly focuses on the development of detection technology and the exploration of impurity generation mechanisms. In terms of detection technology, advanced methods such as Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) and high-resolution mass spectrometry are constantly being explored to achieve precise detection of trace impurities. In the study of impurity generation mechanisms, the causes and influencing factors of its formation are analyzed by simulating drug synthesis reactions and storage environments, providing theoretical support for optimizing the production process and controlling impurity generation. At the same time, research on the impact of this impurity on the efficacy and safety of Lapatinib is also gradually being carried out.
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
